• Image
  • Image
  • Image
  • Image

New RFA from Alzheimer Association and the Gates Foundation

A funding opportunity announced yesterday for early phase clinical trials will be funded through a partnership between the Alzheimer Association and the Gates Foundation: “PART THE CLOUD (PTC) Bioenergetics/ Mitochondria, Clearance Related, Vascular Contributions and Inflammation​ Clinical Trials Program” will accelerate the testing of innovative therapy, including experimental or repurposed drugand/or experimental or repurposed device in the earliest stages of neurodegeneration. For this program, therapeutic approaches to Alzheimer’s disease (AD) and related dementias (ADRD) should have a focus on biological mechanisms related to vascular pathology,mitochondrial/ bioenergetics, clearance related mechanisms (autophagy, lysosomal and lymphatic/ glymphatic systems) and inflammation. Projects will be considered that move experimental or repurposed drug candidates and/or experimental or repurposed trial readydevices into Phase 1 or Phase 2 clinical trials for AD and/or ADRD. Please see all the RFA details about at this link. https://alz.org/research/for_researchers/grants/types-of-grants/partnership_funding_programs/part-the-cloud-gates-2020-partnership